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OBJECTIVES The study evaluated the prognostic value of single measurement of N-terminal pro brain
natriuretic peptide (NT-proBNP) obtained on admission in patients with symptoms
suggestive of an acute coronary syndrome and no ST-segment elevation.
BACKGROUND Patients with symptoms suggestive of an acute coronary syndrome and no ST-segment
elevation constitute a large and heterogeneous population. Early risk stratification has been
based on clinical background factors, electrocardiography (ECG) and biochemical markers of
myocardial damage. The neurohormonal activation has, so far, received less attention.
METHODS The NT-proBNP was analyzed on admission in 755 patients admitted because of chest pain
and no ST-segment elevation. Patients were followed concerning death for 40 months (median).
RESULTS The median NT-proBNP level was 400 (111 to 1646) ng/l. Compared to the lowest quartile,
patients in the second, third and fourth quartiles had a relative risk of subsequent death of 4.2
(1.6 to 11.1), 10.7 (4.2 to 26.8) and 26.6 (10.8 to 65.5), respectively. When NT-proBNP was
added to a Cox regression model including clinical background factors, ECG and troponin
T, the NT-proBNP levels were independently associated with prognosis.
CONCLUSIONS A single measurement of NT-proBNP on admission will substantially improve the early risk
stratification of patients with symptoms suggestive of an acute coronary syndrome and no
ST-segment elevation. A combination of clinical background factors, ECG, troponin T and
NT-proBNP obtained on admission will provide a highly discerning tool for risk stratification
and further clinical decisions. (J Am Coll Cardiol 2002;40:437–45) © 2002 by the
American College of Cardiology Foundation
Patients presenting with chest pain or other symptoms
suggestive of an acute coronary syndrome amount today to
about 20% of all visits to the medical emergency department
(1). Of the two-thirds who will be admitted, about 90% will
have an electrocardiogram (ECG) nondiagnostic of acute
myocardial infarction (AMI) and, thereby, constitute a
heterogeneous group concerning both the underlying
pathophysiology and future risk of cardiac events (2). An
early risk stratification of these patients is important for
several reasons. Those identified as being high-risk patients
might need a more intense pharmacologic treatment and be
considered for intervention early (3). Patients with a low
risk, in contrast, may benefit more from conservative man-
agement with a low risk of side effects. Moreover, consid-
erable economic gains may be achieved by early identifica-
tion of patients who are at sufficiently low risk for early
transfer to a lower level of care and early discharge.
Brain natriuretic peptide (BNP) is a circulating cardiac
hormone that is released mainly from the ventricles in
response to increased stretch or wall tension (4). It is broadly
involved in the regulation of blood pressure, blood volume
and sodium balance; it has in several studies been shown
useful in detecting left ventricular (LV) dysfunction after
AMI and to be related to poor outcome (5–8). Recently, it
was shown that BNP, obtained in the first few days after the
onset of symptoms, also provided important prognostic
information in patients with non–ST-segment elevation
AMI or unstable angina pectoris (9). The BNP is produced
as a prohormone, proBNP, which upon secretion is split
into BNP and N-terminal pro brain natriuretic peptide
(NT-proBNP). A close correlation exists between these
peptides. However, in patients with LV dysfunction, the
proportional and absolute increase of NT-proBNP exceeds
that of BNP, suggesting that NT-proBNP may be a more
discerning marker of LV dysfunction (10).
The aim of the present study was therefore to evaluate the
prognostic value of NT-proBNP analyzed on admission in
patients admitted to the coronary care unit because of chest
pain and an ECG nondiagnostic of AMI.
METHODS
Patient selection. Patients admitted to the coronary care
unit at the Uppsala University Hospital were eligible for
participation between March 1997 and February 1998. The
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inclusion criteria were a history of chest pain or other
symptoms suggestive of an acute coronary syndrome. Ex-
clusion criteria were prehospital thrombolysis, presence of
ST-segment elevation on admission ECG and previous
enrollment in the study. After a run-in period of two
months, consecutive patients were included.
Of the 1,194 eligible patients, 131 were excluded due to
prehospital thrombolysis or ST-segment elevation on ad-
mission ECG and 170 because of previous enrollment in the
study. Frozen plasma samples from 118 randomly selected
patients were used for other purposes. Thus, 775 patients
had an admission-sample available for analysis. Another
sample at 6 h from admission was available in 650 patients.
For the diagnosis of AMI at the index event, one of the
following should be fulfilled: 1) pathologic Q-waves devel-
oping in at least two leads; 2) symptoms suggestive of AMI
and typical elevated levels of biochemical markers with
creatine kinase-MB fraction (mass) 10 g/l; and 3) signs
of AMI at autopsy. All clinical data were prospectively
collected and entered into the local database of the Swedish
Register of Cardiac Intensive Care (11). The treatment of
individual patients was left to the discretion of the individ-
ual physician. The study was approved by the local ethics
committee.
Resting ECG. A 12-lead ECG was obtained on admis-
sion. Patients were divided into four mutually exclusive
groups: 1) those with normal ECG (absence of pathological
Q-waves, bundle branch block, signs of left ventricular
hypertrophy, ST-segment depression, T-wave inversion,
nonsinus rhythm and tachycardia [100 beats/min]); 2)
pathologic changes on ECG other than ST-segment de-
pression or left bundle branch block (LBBB); 3) ST-
segment depression 0.05 mV; and 4) LBBB.
Laboratory analysis. Blood samples were collected in
ethylenediamine-tetraacetic acid-containing tubes. The
samples were then centrifuged, and plasma was stored
frozen in aliquots at 70°C within 30 min. Plasma cardiac
troponin T (cTnT) was later determined by the third-
generation cTnT assay on an Elecsys 2010 (Roche Diag-
nostics, Mannheim, Germany). The analytical range ex-
tends from 0.01 to 25 g/l, and the upper reference level,
defined as the 99th percentile of healthy controls, is below
the lower limit of the analytical range. At the Department of
Clinical Chemistry at the Uppsala Hospital, the intra-assay
CV was 7.9% (n  19) and the interassay was 11.2% (n 
8), at the low end of the analytical range (cTnT  0.037
g/l). Plasma NT-proBNP was determined using Elecsys
proBNP sandwich immunoassay on an Elecsys 2010. The
analytical range extends from 20 to 35,000 ng/l. At our
laboratory the total CV was 3.3% (n  21) at a level of 209
ng/l and 3.0% (n  21) at a level of 7,431 ng/l. The
P-creatinine was assayed at the Department of Clinical
Chemistry on a Hitachi 911 machine (Roche Diagnostics).
Follow-up. The end point was death. All in-hospital
events were registered in the local database of the Swedish
Register of Cardiac Intensive Care (11). Out of hospital,
information about death was obtained from the National
Registry on Mortality. The median follow-up time was 40
months (3.3 years), ranging from 35 to 47 months.
Statistical analysis. All data analysis was performed using
the Statistical Package for Social Sciences (SPSS 10.1)
software (SPSS Inc., Chicago, Illinois). Differences in
proportions were judged by chi-square analysis. If not stated
otherwise, continuous data are given as median-value (25th
to 75th percentile). For continuous data in two independent
groups, the Mann-Whitney U test was used. To compare
paired continuous data, the Wilcoxon matched-pairs signed
rank-sum test was used. The Kruskal-Wallis one-way anal-
ysis of variance was used to test the equality of distributions
in the four NT-proBNP groups. A significant difference was
considered to exist with p  0.05. To evaluate the correla-
tion between the level of NT-proBNP and cTnT, the
Spearman rank-correlation coefficient was calculated. The
Kaplan-Meier method was employed to analyze the timing
of events during follow-up. Statistical assessment was per-
formed using the log-rank test with p  0.05 considered as
significant.
To compare the predictive value of NT-proBNP mea-
sured on admission and that of NT-proBNP measured at
6 h, receiver operating characteristic (ROC) curves were
generated, and the area under the curves calculated. This
approach was also used to investigate the prognostic value of
the relative change of NT-proBNP, defined as (NT-
proBNP at 6 hNT-proBNP on admission)/NT-proBNP
on admission. For the ROC analysis, death at 35 months
was used as the end point. To identify predictors of death,
the univariate Cox regression analyses were used. All vari-
ables with a p 0.10 were then tested in a multivariate Cox
regression analysis using forward stepwise selection. Vari-
ables were entered if p  0.05 and removed if p  0.10.
RESULTS
General findings. The baseline characteristics, findings on
admission ECG and the diagnoses within 24 h of admission
are listed in Table 1. Of 407 patients with AMI or unstable
angina, 68 (17%) and 95 (23%) patients were revascularized
in hospital and 30 days after admission, respectively. During
follow-up, 172 (22%) deaths occurred.
Abbreviations and Acronyms
AMI  acute myocardial infarction
BNP  brain natriuretic peptide
CI  confidence interval
cTnT  cardiac troponin T
ECG  electrocardiogram
LBBB  left bundle branch block
LV  left ventricular
NT-proANP  N-terminal pro atrial natriuretic peptide
NT-proBNP  N-terminal pro brain natriuretic peptide
ROC  receiver operating characteristic
RR  relative risk
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ECG and troponin T. On admission, 242 (31%) patients
had a normal ECG, 252 (33%) ST-segment depression
0.05 mV, 62 (8%) LBBB, and 219 (28%) other pathologic
ECG changes. Compared to those with normal ECG,
patients with other pathologic ECG changes had a relative
risk (RR) of subsequent death of 4.24 (95% confidence
interval [CI]: 2.23 to 8.06), whereas those with ST-segment
depression 0.05 mV and LBBB had an RR of 8.17 (95%
CI: 4.46 to 15.0) and 13.4 (95% CI: 6.83 to 26.1),
respectively. There were 247 (32%) and 271 (42%) patients
with at least one sample of cTnT 0.01 g/l on admission
and after 6 h, respectively. The median cTnT level on
admission was significantly higher in patients who died
during follow-up than in those who survived (0.02 vs.
0.01 g/l, p  0.001). Patients with a cTnT 0.01 g/l
on admission had a 3.2-fold increased risk of death com-
pared to those without.
NT-proBNP. The median value of NT-proBNP on ad-
mission was 400 (111 to 1,646) ng/l. A total of 650 patients
had NT-proBNP analyzed also at 6 h, with a median value
of 525 (122 to 2,228) ng/l. The relationship between
NT-proBNP level on admission and clinical background
factors is shown in Table 1. Patients with a diagnosis of
AMI or other cardiac causes had the highest levels of
NT-proBNP, whereas those with noncardiac or unknown
causes had the lowest levels (Table 2). At 6 h, there was a
significant increase of NT-proBNP in all groups, with the
largest increase in the group with AMI. The group with a
cTnT 0.01 g/l on admission had a median level of
NT-proBNP of 204 (72 to 738) ng/l. In patients with a
cTnT 0.01 g/l, the median level was 1,639 (491 to
5,382). In the latter group, a moderate correlation existed
between the level of cTnT and that of NT-proBNP (rho
0.49, p  0.01).
Predictive value of NT-proBNP. The risk of death during
follow-up increased with increasing levels of NT-proBNP
on admission (Fig. 1). Compared to the lowest quartile,
patients in the second, third, and fourth quartiles had an RR
(95% CI) of subsequent death of 4.2 (1.6 to 11.1), 10.7 (4.2
to 26.8) and 26.6 (10.8 to 65.5), respectively. Patients with
Table 1. Baseline Characteristics of the Study Population (n  775)
Characteristics
NT-proBNP
<112 ng/l
(n  195)
NT-proBNP
113–400 ng/l
(n  193)
NT-proBNP
401–1,653 ng/l
(n  194)
NT-proBNP
>1,654 ng/l
(n  193) p Value
Age, median (25th–75th percentile), years 55 (48–64) 70 (59–76) 75 (68–80) 77 (70–83)  0.001
Men 134 (69) 111 (58) 110 (57) 113 (58) 0.053
Diabetes mellitus 25 (13) 24 (12) 32 (16) 50 (26) 0.001
Hypertension 52 (27) 75 (39) 94 (48) 89 (46)  0.001
Current smoker 39 (20) 34 (18) 22 (11) 35 (18) 0.116
Previous myocardial infarction 32 (16) 64 (33) 78 (40) 86 (45)  0.001
Previous revascularization 22 (11) 43 (22) 40 (21) 23 (12) 0.003
Previous congestive heart failure 6 (3) 27 (14) 58 (30) 85 (44)  0.001
Medication at admission
Aspirin 58 (30) 91 (47) 104 (54) 82 (42)  0.001
Beta-blockers 45 (23) 78 (40) 82 (42) 88 (46)  0.001
Nitrates 21 (11) 45 (23) 69 (36) 69 (36)  0.001
Calcium antagonists 26 (13) 42 (22) 49 (25) 31 (16) 0.012
Diuretics 2 (1) 5 (3) 24 (12) 45 (23)  0.001
ACE inhibitors 20 (10) 36 (19) 49 (25) 77 (40)  0.001
Digoxin 17 (9) 14 (7) 18 (9) 22 (11) 0.561
Time from onset of chest pain to admission, 4.7 (2.9–9.0) 5.5 (2.7–11) 5.8 (3.8–11) 6.2 (3.8–11) 0.03
median (25th–75th percentile), h*
ECG on admission
Normal ECG 129 (66) 78 (40) 29 (15) 6 (3)  0.001
Other pathologic ECG 49 (25) 59 (31) 64 (33) 47 (24) 0.168
ST-depression 0.05 mV 11 (6) 53 (27) 79 (41) 109 (56)  0.001
LBBB 6 (3) 3 (2) 22 (11) 31 (6)  0.001
Troponin T 0.01 g/l on admission 13 (7) 39 (20) 73 (38) 122 (63)  0.001
P-creatinine  120 mmol/l† 11 (6) 19 (11) 38 (21) 76 (42)  0.001
Treatment in hospital
Unfractionated or LMW heparin 16 (8) 45 (23) 47 (24) 51 (26)  0.001
Nitroglycerin IV 7 (4) 16 (8) 27 (14) 37 (19)  0.001
Diagnosis within 24 h from admission
Acute myocardial infarction 13 (7) 38 (20) 57 (29) 67 (35)  0.001
Unstable angina/angina 50 (26) 64 (33) 74 (38) 44 (23) 0.004
Other cardiac causes‡ 8 (4) 15 (8) 23 (12) 51 (26)  0.001
Noncardiac/unknown causes 124 (64) 76 (39) 40 (21) 31 (16)  0.001
If not stated otherwise, the values shown are the number of patients and percentages of the group. *Evaluable in 173/179/170/165 of the patients. †Evaluable in 185/178/183/182
of the patients. ‡Such as congestive heart failure, arrhythmias and peri- or myocarditis.
ACE angiotensin-converting enzyme; ECG electrocardiogram; LBBB left bundle branch block; LMW low molecular weight; NT-proBNPN-terminal pro brain
natriuretic peptide.
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elevated NT-proBNP had an increased risk irrespective of
diagnosis (Fig. 2). When the predictive value of NT-
proBNP measured on admission and the value of NT-
proBNP measured at 6 h were compared in an ROC
analysis, the areas under the curves were almost identical
(Fig. 3). As compared to patients who survived, patients
who died had a larger increase of NT-proBNP between
admission and at 6 h (median: 334 vs. 26 ng/l, p  0.001).
The relative change did not differ significantly between the
groups (19% vs. 16%, p  0.07) and carried no prognostic
information according to the ROC analysis (Fig. 3). The
RR (95% CI) of subsequent death was 1.00 (0.56 to 1.8) and
1.28 (0.75 to 2.18) in patients with unchanged (10%) and
with increasing NT-proBNP levels between admission and
6 h, respectively, compared to patients with decreasing
levels.
Multivariate analyses. In a Cox regression model, increas-
ing age, diabetes, ECG changes, elevated cTnT and
P-creatinine proved to be independent predictors of mor-
tality (Table 3, model 1). When proBNP measured on
admission was added, NT-proBNP levels, but not ECG
changes, were independently associated with prognosis (Ta-
ble 3, model 2). When time of delay from start of symptoms
to admission and diagnosis was forced into the final model,
the association between NT-proBNP levels and prognosis
remained unchanged. The predictive value of NT-proBNP
was apparent both in patients with and without an elevated
cTnT and in patients with different risks according to the
ECG on admission (Figs. 4 and 5).
DISCUSSION
The aim was to study a nonselected population, similar to
the one dealt with in clinical practice. Accordingly, consec-
utive patients admitted to the coronary care unit were
included with no requirements of ECG changes on admis-
sion or raised biochemical markers of myocardial damage,
excluding only patients with definite diagnosis based on
Table 2. The Relation Between the Level of NT-proBNP and Diagnosis
NT-proBNP
on Admission
NT-proBNP
at 6 h*
NT-proBNP
Change*
Noncardiac causes/unknown causes 126 (49–415) 127 (54–389)† 6 (8–42)
Unstable angina/angina 409 (130–1,389)‡ 600 (150–1,555)†‡ 40 (0–268)
Other cardiac causes 1,821 (598–3,973)‡ 2,256 (629–4,928)†‡ 208 (2.5–682)
Acute myocardial infarction 1,089 (326–3,668) 2,008 (707–5,944)† 449 (122–1,474)
Values shown are medians and 25th to 75th percentiles. *Available in 650 patients. †p  0.001, each group compared to the
group on its left. ‡p  0.001, each group compared to the group above.
NT-proBNP  N-terminal pro brain natriuretic peptide.
Figure 1. Cumulative probability of death in patients with: 1) NT-proBNP112 ng/l (n 195); 2) NT-proBNP 113–400 ng/l (n 193); 3) NT-proBNP
401–1,653 ng/l (n  194); and 4) NT-proBNP 1,654 ng/l (n  195). 1 vs. 2: log-rank p  0.005; 2 vs. 3 and 3 vs. 4: log-rank p  0.001. The curves
are terminated when 10 patients remain at risk. NT-proBNP  N-terminal pro brain natriuretic peptide.
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ST-segment elevation. This was reflected by a fairly low
incidence of cTnT 0.01 g/l (32%) and by the fact that
patients were older, with a higher mortality compared to
studies that included a more selected population (9,12).
Patients were enrolled from March 1997 to February 1998,
during which a conservative approach, one with few early
revascularizations, was still in use in our institution.
Predictors of outcome. In accordance with previous stud-
ies (12–14), several clinical background factors were associ-
ated with poor outcome. In a multivariate analysis, increas-
ing age, diabetes, previous AMI, elevated P-creatinine,
ECG changes and elevated cTnT were independent pre-
dictors of mortality. When adjusted for baseline character-
istics and the level of cTnT, only a small difference was seen
between the predictive value of ST-segment depression and
that of other pathologic signs. This may indicate that, in
patients without ST-segment elevation or LBBB, the ab-
sence of a normal ECG, rather than the presence of
ST-segment depression, is the main determinant of out-
come. However, both ECG and cTnT were probably
underestimated as predictors in the present study. Contin-
uous monitoring and repeated measurements have been
shown to improve the prognostic performance of ECG and
cTnT, respectively (15,16).
NT-proBNP. The present study is the first one to dem-
onstrate that a single measurement of NT-proBNP, ob-
tained on admission, provides important prognostic infor-
mation in the large population of patients with symptoms
suggestive of an acute coronary syndrome but with an ECG
without ST-segment elevation. When patients were divided
according to diagnosis into those with AMI, unstable
angina, other cardiac causes and other noncardiac or un-
known causes, the prognostic value of NT-proBNP was
evident in all groups. Moreover, when the level of NT-
Figure 2. Cumulative probability of death in patients with (A) acute myocardial infarction (n1–3  51, 57, 67) pooled log-rank p  0.001; (B) angina or
unstable angina (n1–4  50, 64, 74, 44) pooled log-rank p  0.001; (C) other cardiac causes (n1–3  23, 23, 51) pooled log-rank p  0.004; (D) other
noncardiac or unknown causes (n1–4  124, 76, 40, 31) pooled log-rank p  0.001. The curves are terminated when 10 patients remain at risk.
NT-proBNP  N-terminal pro brain natriuretic peptide.
441JACC Vol. 40, No. 3, 2002 Jernberg et al.
August 7, 2002:437–45 NT-proBNP in Chest Pain Patients
proBNP was tested in a multivariate analysis including
well-known predictors of outcome, such as age, diabetes,
history of previous myocardial infarction, congestive heart
failure, ECG changes and cTnT, the NT-proBNP was still
an important independent predictor of outcome.
Natriuretic peptides have been shown to be useful for
detection of LV dysfunction and to be related to poor
outcome in patients with AMI (5–8,17–19). However,
there are still few studies that have examined this area,
including patients with unstable angina or non-ST-segment
elevation AMI. In a recent study by de Lemos et al. (9),
BNP was measured in a cohort including 1,698 patients
with unstable angina or non-ST-segment elevation AMI. In
that study, the 10-month mortality increased with increas-
ing levels of BNP, with a mortality of approximately 1% in
the lowest quartile and 7% to 15% in the highest quartile. In
another study (20), our group measured N-terminal pro
atrial natriuretic peptide (NT-proANP) in 104 patients
with unstable angina or non-ST-segment elevation AMI. In
that study, patients with elevated NT-proANP had a
fivefold increased risk of death during a median follow-up
time of 48 months. Further support has been provided by
Omland et al. (21) reporting higher levels of both NT-
proANP and NT-proBNP in patients who died after an
episode of acute coronary syndrome compared to a group of
matched controls. In all three studies, an elevated level of
the natriuretic peptide was an independent predictor of
mortality when adjusted for clinical background factors,
ECG changes and levels of troponin. However, in contrast
to the present study, the two former studies measured
natriuretic peptide approximately two days after the index
event.
Furthermore, NT-proBNP and BNP have been sug-
gested to be better indicators of LV dysfunction and poor
outcome than NT-proANP and ANP (7,8,19). Although
NT-proBNP and BNP are highly correlated, the propor-
tional and absolute increase above normal levels of NT-
proBNP exceeds that for BNP in patients with LV dysfunc-
tion (10). This may indicate that NT-proBNP is a more
discerning marker of cardiac dysfunction and poor outcome.
One measurement of NT-proBNP on admission identi-
fied a low-risk group with cumulative probability of death of
3%, and a high-risk group with cumulative probability of
death of 55%. In a majority of patients, the level of
NT-proBNP increased at 6 h from admission, with the
highest increase in patients with AMI. However, when the
predictive values of NT-proBNP measured on admission
and that of NT-proBNP measured at 6 h were compared in
an ROC analysis, the areas under the curves were almost
identical. Furthermore, the relative change of NT-proBNP
did not carry any prognostic information. This may indicate
that the incremental value of serial measurements is limited.
Figure 3. Receiver operating characteristic curve concerning death at 35 months for NT-proBNP on admission, NT-proBNP at 6 h, and the relative change
with an area under the curve (95% confidence interval) of 0.820 (0.784–0.856), 0.822 (0.786–0.857), and 0.554 (0.497–0.611), respectively.
NT-proBNP  N-terminal pro brain natriuretic peptide.
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At least two possible mechanisms can explain the relation
between NT-proBNP level and prognosis in the present
population. First, an elevated NT-proBNP may reflect a
permanent LV dysfunction established prior to or during
the current episode of instability, which is an important
predictor of outcome in patients with acute coronary syn-
dromes (22). Second, it can also reflect a temporary LV
dysfunction secondary to transient ischemic episodes jeop-
ardizing a large part of the myocardium. Previous studies
have demonstrated elevation of BNP shortly after percuta-
neous coronary intervention (23). Thus, an elevated NT-
proBNP does not necessarily reflect a neurohormonal acti-
Table 3. Cox Regression Analysis
Univariate Analysis
Multivariate Analysis
Model 1 Model 2
RR (95% CI) p Value RR (95% CI) RR (95% CI)
Age (10 yrs) 2.20 (1.87–2.59)  0.001 1.93 (1.60–2.33) 1.74 (1.43–2.12)
Men 1.03 (0.76–1.40) 0.859
Diabetes mellitus 2.05 (1.46–2.89)  0.001 1.61 (1.11–2.35) 1.49 (1.02–2.16)
Hypertension 1.25 (0.92–1.70) 0.145
Current smoker 1.30 (0.89–1.89) 0.178
Previous myocardial infarction 2.00 (1.48–2.71)  0.001 1.41 (1.02–1.96)
Previous revascularization 0.71 (0.46–1.12) 0.139
Previous congestive heart failure 2.60 (1.91–3.53)  0.001
Medication at admission
Aspirin 1.20 (0.89–1.62) 0.237
Beta-blockers 1.10 (0.81–1.49) 0.554
Nitrates 1.95 (1.43–2.66)  0.001
Calcium antagonists 1.04 (0.71–1.52) 0.837
Diuretics 2.86 (1.96–4.17)  0.001
ACE inhibitors 1.80 (1.31–2.48)  0.001
Digoxin 1.42 (0.89–2.27) 0.140
ECG on admission
Normal ECG 1 1
Other pathological ECG 4.24 (2.23–8.06)  0.001 2.69 (1.40–5.18)
ST-depression 0.05 mV 8.17 (4.46–15.0)  0.001 2.92 (1.55–5.51)
LBBB 13.4 (6.83–26.1)  0.001 4.07 (2.01–8.27)
Troponin T 0.01 g/l on admission 3.17 (2.34–4.29)  0.001 1.88 (1.36–2.61) 1.61 (1.14–2.27)
P-creatinine 120 mmol/l 3.59 (2.60–4.95)  0.001 1.98 (1.41–2.79) 1.60 (1.12–2.27)
NT-proBNP on admission
112 ng/l 1 1
113–400 ng/l 4.15 (1.56–11.1) 0.004 — 1.85 (0.67–5.08)
401–1,653 ng/l 10.7 (4.24–26.8)  0.001 — 2.96 (1.12–7.81)
1,654 ng/l 26.6 (10.8–65.5)  0.001 — 5.40 (2.02–14.4)
ACE  angiotensin-converting enzyme; CI  confidence interval; ECG  electrocardiogram; LBBB  left bundle branch
block; NT-proBNP  N-terminal pro brain natriuretic peptide; RR  relative risk.
Figure 4. Positive predictive value concerning death at 35 months in relation to troponin T and NT-proBNP level on admission. Number of patients in
each group is shown on each bar. NT-proBNP  N-terminal pro brain natriuretic peptide; cTnT  cardiac troponin T. Open bars  NT-proBNP 
401 ng/l; solid bars  NT-proBNP  1,653 ng/l; hatched bars  NT-proBNP 401–1,653 ng/l.
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vation or cell leakage in response to myocardial necrosis.
The fact that the event curves continued to separate up to
four years supports the theory that raised levels of NT-
proBNP reflect LV dysfunction or a large area of myocar-
dium at jeopardy.
To be useful, a clinical risk indicator should not only
identify patients with increased risk, but also patients who
benefit from a certain treatment, and thereby be able to
guide treatment. Troponin and ECG changes have previ-
ously been shown to identify patients with a high risk of
subsequent cardiac events and who benefit most from
intensive antithrombotic treatment and early revasculariza-
tion (24–27). A previous study (28) showed that treatment
of heart failure guided by NT-proBNP concentrations
resulted in a better outcome than treatment guided by
clinical assessment. It is therefore tempting to suggest that
patients with elevated NT-proBNP will benefit from an
early aggressive treatment with neurohormonal antagonism
(such as angiotensin-converting enzyme inhibitors and
beta-blockade) and early revascularization in addition to an
intense antithrombotic treatment. However, this needs to
be evaluated in future studies. Conversely, patients with a
low level of NT-proBNP on admission and a low risk of
subsequent events will probably benefit most from a con-
servative management with a low risk of side effects.
Study limitations. There are some limitations with the
present study. There was no systematic evaluation of LV
function. It is generally acknowledged that LV function is
one of the most important predictors of outcome in patients
with acute coronary syndrome (22). Previous studies have
suggested BNP and NT-proBNP to be better predictors of
outcome (7,19). Therefore, it would have been interesting to
compare the LV ejection fraction determined by echocar-
diography with measurement of NT-proBNP in the present
population. Another limitation is that NT-proBNP was
only measured during the first 6 h from admission. In
patients with AMI, NT-proBNP continues to increase
during the first 24 h (29,30). Thus, although the level of
NT-proBNP at 6 h from admission did not add any
prognostic information, measurement later in the course of
instability might still be of additive value.
Conclusions. The early risk stratification of patients with
symptoms suggestive of an acute coronary syndrome and an
ECG without ST-segment elevation has been based on
clinical background factors, the acute clinical presentation,
ECG measurements and biochemical markers of myocardial
damage. The neurohormonal activation has, so far, received
less attention. This study shows that a single measurement
of NT-proBNP on admission will substantially improve this
process, and that a combination of clinical background
factors, ECG, troponin T and NT-proBNP obtained on
admission will provide a highly discerning tool for risk
stratification and further clinical decisions.
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